English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Next-generation sequencing technologies for DNA methylation analyses in cancer genomics

MPS-Authors

Boerno,  Stefan T.
Max Planck Society;

/persons/resource/persons50173

Grimm,  Christina
In vitro Ligand Screening (Zoltán Konthur), Dept. of Vertebrate Genomics (Head: Hans Lehrach), Max Planck Institute for Molecular Genetics, Max Planck Society;

/persons/resource/persons50409

Lehrach,  Hans
Dept. of Vertebrate Genomics (Head: Hans Lehrach), Max Planck Institute for Molecular Genetics, Max Planck Society;

/persons/resource/persons50543

Schweiger,  Michal-Ruth
Cancer Genomics (Michal-Ruth Schweiger), Dept. of Vertebrate Genomics (Head: Hans Lehrach), Max Planck Institute for Molecular Genetics, Max Planck Society;

External Resource
No external resources are shared
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Boerno, S. T., Grimm, C., Lehrach, H., & Schweiger, M.-R. (2010). Next-generation sequencing technologies for DNA methylation analyses in cancer genomics. Epigenomics, 2(2), 199-207. doi:10.2217/epi.09.50.


Cite as: http://hdl.handle.net/11858/00-001M-0000-0010-7B7A-6
Abstract
For the first time, the development of next-generation sequencing technologies has brought about tools to investigate epigenetic alterations in an unbiased, yet genome-wide approach. The importance of this innovative technology is undeniable since it has already been established that changes in DNA methylation play an important role in cancer initiation and progression. The first methylation maps have already been created, and it is only a matter of time until the complete epigenetic maps of healthy and diseased human genomes are available. In this review, we summarize the use of next-generation sequencing for diverse epigenetic technologies, give an overview of the status quo and outline future perspectives for its application in oncology and basic research.